Investment Thesis
Establishment Labs exhibits strong revenue growth (27.1% YoY) and excellent gross margins (70.7%), indicating solid product economics in the orthopedic device market. However, the company remains deeply unprofitable with negative operating cash flow (-$4.3M) despite revenue growth, and carries extreme leverage (Debt/Equity of 16.82x) on a dangerously thin equity base ($14.8M), creating significant financial distress risk if profitability targets are not achieved imminently.
Strengths
- Strong revenue growth of 27.1% YoY indicating market demand and scale
- Excellent gross margins of 70.7% demonstrating strong product economics and pricing power
- Adequate short-term liquidity with current ratio of 2.96x and cash position of $68.1M
Risks
- Extreme leverage with Debt/Equity ratio of 16.82x and $248.6M long-term debt relative to $14.8M equity—high default risk
- Negative free cash flow of -$6.2M despite revenue growth indicates business not self-sustaining and unsustainable burn trajectory
- Negative operating income (-$6.5M, -10.9% margin) and net income (-$13.4M, -22.3% margin) with no clear path to profitability timeline
- Negative interest coverage (-0.4x) means operating losses cannot service debt obligations
Key Metrics to Watch
- Operating cash flow trend—critical to assess sustainability; negative FCF despite revenue growth is unsustainable
- Path to operating profitability—company must reach positive operating margin to justify debt burden
- Debt reduction progress—with extreme leverage, any debt repayment or refinancing developments are critical
Financial Metrics
Revenue
59.9M
Net Income
-13.4M
EPS (Diluted)
$-0.45
Free Cash Flow
-6.2M
Total Assets
351.0M
Cash
68.1M
Profitability Ratios
Gross Margin
70.7%
Operating Margin
-10.9%
Net Margin
-22.3%
ROE
-90.5%
ROA
-3.8%
FCF Margin
-10.3%
Balance Sheet & Liquidity
Current Ratio
2.96x
Quick Ratio
1.91x
Debt/Equity
16.82x
Debt/Assets
95.8%
Interest Coverage
-0.44x
Long-term Debt
248.6M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-09T08:47:49.990010 |
Data as of: 2026-03-31 |
Powered by Claude AI